Event List
retrieve:
Return the details about the given Event id.
list:
List all Event objects.
GET /api/v1/events/?format=api&offset=210&ordering=event__id
{ "count": 214, "next": null, "previous": "https://memento.epfl.ch/api/v1/events/?format=api&limit=10&offset=200&ordering=event__id", "results": [ { "id": 71948, "title": "U.S. CDMRP – Lung Cancer Research Program | Research Funding", "slug": "us-cdmrp-lung-cancer-research-program-research-f-6", "event_url": "https://memento.epfl.ch/event/us-cdmrp-lung-cancer-research-program-research-f-6", "visual_url": "https://memento.epfl.ch/image/33256/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33256/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33256/max-size.jpg", "lang": "en", "start_date": "2026-06-23", "end_date": "2026-06-23", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Lung Cancer Research Program</strong> <strong>(LCRP)</strong> Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Idea Development Award</strong> Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.</li>\r\n\t<li>The <strong>Patient-Centered Outcomes and Survivorship Award</strong> Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications.</li>\r\n\t<li>The <strong>Translational Research Award</strong> mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application.</li>\r\n</ul>\r\nAll applications for LCRP funding must specifically address at least one of the <strong>Areas of Emphasis</strong>. The FY26 LCRP Areas are listed at the end of this announcement.<br>\r\n<br>\r\n<strong>Funding</strong>: <br>\r\nIdea Development Award: max. $800K<br>\r\nPatient-Centered Outcomes and Survivorship Award: max. $975K<br>\r\nTranslational Research Award: $1.35M – $1.85M<br>\r\n<sup><sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub></sup><br>\r\n<br>\r\n<strong>Duration</strong>: <br>\r\nIdea Development Award: 3 years<br>\r\nPatient-Centered Outcomes and Survivorship Award: 3 years<br>\r\nTranslational Research Award: 3-4 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Program-specific seniority levels and eligibility criteria are further defined within each award mechanism <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221239&fileType=pdf\">here</a>.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: </strong>\r\n\r\n<ul>\r\n\t<li><strong>23 June 2026, </strong>5:00 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Idea Development Award</li>\r\n\t\t<li>Translational Research Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>18 August 2026, </strong>5:00 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Patient-Centered Outcomes and Survivorship Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<strong>Full Application Deadline for all calls</strong>:\r\n\r\n<ul>\r\n\t<li><strong>02 September 2026</strong>, 11:59 p.m Eastern Time</li>\r\n</ul>\r\n <br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719103\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221239&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a></li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Idea Development Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221233&fileType=pdf\">HT942526LCRPIDA</a></li>\r\n\t\t<li>Patient-Centered Outcomes and Survivorship Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221308&fileType=pdf\">HT942526LCRPPCOSA</a></li>\r\n\t\t<li>Translational Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221292&fileType=pdf\">HT942526LCRPTRA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>FY26 LCRP Areas of Emphasis</strong>\r\n\r\n<ul>\r\n\t<li>Biology and Etiology\r\n\t<ul>\r\n\t\t<li>Understand the molecular mechanisms of initiation and progression of pre-malignancy to lung cancer.</li>\r\n\t\t<li>Understand contributors to lung cancer development other than tobacco, including hereditary and sex-specific differences.</li>\r\n\t\t<li>Understand the biology of metastatic/oligometastatic disease progression.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Prevention and Risk Reduction\r\n\t<ul>\r\n\t\t<li>Identify innovative strategies for the prevention and/or interception of lung cancer development.</li>\r\n\t\t<li>Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Detection, Diagnosis and Surveillance\r\n\t<ul>\r\n\t\t<li>Improve and expand approaches to screening and early detection of lung cancer.</li>\r\n\t\t<li>Identify strategies for prompt detection and/or characterization of progressive disease.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Treatment and Prognosis\r\n\t<ul>\r\n\t\t<li>Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.</li>\r\n\t\t<li>Develop or optimize biomarkers to assist with therapeutic decision-making.</li>\r\n\t\t<li>Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Health Outcomes and Survivorship\r\n\t<ul>\r\n\t\t<li>Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on quality of life for patients and families.</li>\r\n\t\t<li>Identify and understand the impact of comorbidities on survivorship care in all stages of lung cancer.</li>\r\n\t\t<li>Reduce differences among high-risk groups and populations.</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-26T19:15:50", "last_modification_date": "2026-05-26T19:15:50", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120861/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api" ] }, { "id": 71949, "title": "U.S. CDMRP – Amyotrophic Lateral Sclerosis Research Program | Research Funding", "slug": "us-cdmrp-amyotrophic-lateral-sclerosis-research--4", "event_url": "https://memento.epfl.ch/event/us-cdmrp-amyotrophic-lateral-sclerosis-research--4", "visual_url": "https://memento.epfl.ch/image/33257/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33257/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33257/max-size.jpg", "lang": "en", "start_date": "2026-06-24", "end_date": "2026-06-24", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Amyotrophic Lateral Sclerosis Research Program (ALSRP) </strong>Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Clinical Outcomes and Biomarkers Award </strong>supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Applications must address at least one of the focus areas listed <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35925310&fileType=pdf\">here</a>.</li>\r\n\t<li>The <strong>Pilot Clinical Trial Award </strong>supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or symptom management of ALS. Proposed projects may range from phase 1 to small-scale phase 2 trials. Applications must address at least one of the focus areas listed <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35927287&fileType=pdf\">here</a>.</li>\r\n\t<li>The <strong>Therapeutic Development Award </strong>supports research ranging from preclinical validation of therapeutic leads through FDA IND-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology. Candidate therapeutics that already have been granted an IND are not appropriate for the TDA.</li>\r\n\t<li>The <strong>Therapeutic Idea Award </strong>supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.</li>\r\n</ul>\r\n<strong>Funding</strong>: \r\n\r\n<ul>\r\n\t<li>Clinical Outcomes and Biomarkers Award: max. $1M</li>\r\n\t<li>Pilot Clinical Trial Award: max. $2.8M</li>\r\n\t<li>Therapeutic Development Award: max. $2M</li>\r\n\t<li>Therapeutic Idea Award: max. $840K</li>\r\n</ul>\r\n<sup>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sup><br>\r\n<br>\r\n<strong>Duration</strong>: \r\n\r\n<ul>\r\n\t<li>Clinical Outcomes and Biomarkers Award: 3 years</li>\r\n\t<li>Pilot Clinical Trial Award: 3 years</li>\r\n\t<li>Therapeutic Development Award: 3 years</li>\r\n\t<li>Therapeutic Idea Award: 2 years</li>\r\n</ul>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: 24 June 2026, </strong>5:00 p.m. Eastern time<br>\r\n<strong>Full Application Deadline</strong>: <strong>30 September 2026</strong>, 11:59 p.m Eastern Time<br>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707101\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241278&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Clinical Outcomes and Biomarkers Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35925310&fileType=pdf\">HT942526ALSRPCOBA</a></li>\r\n\t\t<li>Pilot Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35927287&fileType=pdf\">HT942526ALSRPPCTA</a></li>\r\n\t\t<li>Therapeutic Development Award : <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35921227&fileType=pdf\">HT942526ALSRPTDA</a></li>\r\n\t\t<li>Therapeutic Idea Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35919305&fileType=pdf\">HT942526ALSRPTIA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-26T19:57:31", "last_modification_date": "2026-05-26T19:57:31", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120862/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api" ] }, { "id": 71950, "title": "U.S. CDMRP – Peer Reviewed Cancer Research Program | Research Funding", "slug": "us-cdmrp-peer-reviewed-cancer-research-program-res", "event_url": "https://memento.epfl.ch/event/us-cdmrp-peer-reviewed-cancer-research-program-res", "visual_url": "https://memento.epfl.ch/image/33258/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33258/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33258/max-size.jpg", "lang": "en", "start_date": "2026-06-26", "end_date": "2026-06-26", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Peer Reviewed Cancer Research Program (PRCRP). </strong>Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Idea Award </strong>supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to active-duty Service Members, Veterans, other military beneficiaries, and the American public.</li>\r\n\t<li>The <strong>Impact Award</strong> supports mature research that will have a near-term impact on clinical cancer care in one of the Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the MHS.</li>\r\n\t<li>The <strong>Clinical Trial Award </strong>supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.</li>\r\n</ul>\r\nAll applications must specifically address at least one of the <strong>Topic Areas. </strong>The FY26 PRCRP Topic Areas are listed at the end of this announcement.<br>\r\n<br>\r\n<strong>Funding</strong>: <br>\r\n<strong>Idea Award</strong>: max. $600K<br>\r\n<strong>Impact Award</strong>: $1.5M-$2M<br>\r\n<strong>Clinical Trial Award</strong>: max. $4.5M<br>\r\n<sup>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sup><br>\r\n<br>\r\n<br>\r\n<strong>Duration</strong>: <br>\r\n<strong>Idea Award</strong>: 2 years<br>\r\n<strong>Impact Award</strong>: 3 years<br>\r\n<strong>Clinical Trial Award: </strong>4 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: 26 June 2026, </strong>5:00 p.m. Eastern time<br>\r\n<strong>Full Application Deadline</strong>: <strong>05 October 2026</strong>, 11:59 p.m Eastern Time<br>\r\n <br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719105\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36245281&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Idea Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36235224&fileType=pdf\">HT942526PRCRPIA</a></li>\r\n\t\t<li>Impact Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36235237&fileType=pdf\">HT942526PRCRPIPA</a></li>\r\n\t\t<li>Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36235233&fileType=pdf\">HT942526PRCRPCTA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<strong>FY26 </strong><strong>PRCRP Topic Areas:</strong><br>\r\nBladder cancer • Blood cancers • Brain cancer • Colorectal cancer • Endometrial cancer • Esophageal cancer • Germ cell cancers • Glioblastoma • Liver cancer • Lymphoma • Mesothelioma • Metastatic cancers • Myeloma • Neuroblastoma • Neuroendocrine Tumors • Pediatric, adolescent, and young adult cancers1 • Pediatric brain tumors • Sarcoma • Stomach cancer • Thyroid cancer<br>\r\n ", "image_description": "", "creation_date": "2026-05-26T20:48:08", "last_modification_date": "2026-05-26T20:48:08", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120863/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api" ] }, { "id": 71951, "title": "Topology of spatiotemporal trajectories", "slug": "topology-of-spatiotemporal-trajectories-2", "event_url": "https://memento.epfl.ch/event/topology-of-spatiotemporal-trajectories-2", "visual_url": "https://memento.epfl.ch/image/33259/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33259/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33259/max-size.jpg", "lang": "en", "start_date": "2026-05-28", "end_date": "2026-05-28", "start_time": "10:00:00", "end_time": "11:00:00", "description": "<p>In recent years, multiparameter persistent homology (MPH) has been developed to address the limitations of traditional single-parameter persistence. While much progress has been made on the theoretical aspects of MPH, practical applications have mostly been limited to the special case of two parameters. Building on recent developments in the computation of MPH in more than two parameters, we propose and implement a new algorithm for the computation of multiparameter persistence landscapes in this setting. We apply this work to compute landscapes of three-parameter persistence modules built on spatiotemporal data arising in biology.<br>\r\n </p>", "image_description": "", "creation_date": "2026-05-27T07:49:48", "last_modification_date": "2026-05-27T07:50:08", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "CM 1 517", "url_place_and_room": "https://plan.epfl.ch/?room==CM%201%20517", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "Kate Benjamin, University of Oxford", "organizer": "Joseph Griggs", "contact": "Maroussia Schaffner", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120865/", "category": { "id": 1, "code": "CONF", "fr_label": "Conférences - Séminaires", "en_label": "Conferences - Seminars", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api" ] } ] }
